



# CI C-DIM 12

### References

 Zhu et al. (2009) Cell Stem Cell 4 416

Stauprimide

- Kiselyuk et al. (2012) Chem. Biol. 19 806
- 3. Hur et al. (2010) Chem. Biol. 17 537
- Grant et al. (2012) Proc. Natl. Acad. Sci. 109 4503
- 5. Yin et al. (2003) Oncogene **22** 6151
- 6. Handeli *et al.* (2008) Mol. Cancer Ther. **7** 521
- 7. Yu *et al.* (2011) Diabetologia **54** 922
- 8. Park *et al.* (1999) Bull. Korean Chem. Soc. **20** 925
- 9. De Miranda *et al.* (2015) Mol. Pharmacol. **87** 1021

## **Transcription Factor Modulators**

### Stauprimide

Inhibits nuclear localization of NME2, a c-Myc-activating transcription factor. Primes embryonic stem cells for differentiation.<sup>1</sup>

10-1189

1 mg / \$85.00, 5 mg / \$380.00

### BI-6015

Antagonizes HNF4 $\alpha$ , a transcription factor that controls metabolic homeostasis and epithelial differentiation. BI-6015 (1-10  $\mu$ M) inhibits the expression of HNF4 $\alpha$  target genes, reduces insulin production in T6PNE cells and is cytotoxic to a number of cancer cell lines. 10-1402 5 mg / \$48.00, 25 mg / \$192.00

### AI-1

Activates Nrf2, a transcriptional regulator of cellular antioxidant responses.<sup>3</sup> Nrf2 is negatively regulated via ubiquitination by the Cul3-Keap1 ubiquitin ligase complex. Al-1 covalently modifies Keap1 and prevents it from serving as an adaptor for the complex, resulting in stabilization and transcriptional activation of Nrf2.

10-1471

5 mg / \$70.00, 25 mg / \$280.00

### FOL

Factor quinolinone inhibitor 1 (FQI1), inhibits late SV40 factor (LSF), a transcription factor highly expressed in hepatocellular carcinoma (HCC). FQI1 inhibits LSF DNA-binding and induces cell death in HCC cells but not primary hepatocytes.<sup>4</sup>

10-1360

5 mg / \$70.00, 25 mg / \$280.00

### 10058-F4

A c-Myc inhibitor that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. Inhibits proliferation, induces apoptosis and arrests cells in G0/G1 in rat1a-c-Myc cells. Also reduces tumor growth *in vivo*.

10-1466

5 mg / \$50.00, 25 mg / \$200.00

### FH-535

Suppresses Wnt/ $\beta$ -catenin signaling. It antagonizes PPAR ligand-dependent activation mediated by inhibition of recruitment of the coactivators  $\beta$ -catenin and GRIP1 but not the corepressors NCoR and SMRT. Inhibits the migration and growth of breast cancer cells. 10-1328 10 mg / \$50.00, 50 mg / \$200.00

## Oltipraz

Upregulates the transcription factor Nrf2 and prevents insulin resistance and obesity induced by high fat diet in C57BL/6J mice.<sup>7</sup>

10-2831

50 mg / \$39.00, 250 mg / \$156.00

### Tanshinone IIA

Inhibits AP-1 activity by suppressing jun-fos-DNA complex formation (IC<sub>50</sub> = 0.22  $\mu$ M).

10-2186

5 mg / \$80.00, 25 mg / \$280.00

### **C-DIM 12**

Activates the orphan nuclear receptor Nurr1 which is a suppressor of NF $\kappa$ B-dependent proinflammatory genes. Displays neuroprotective activity in a mouse model of progressive neurodegeneration with a strong neuroinflammatory component (50 mg / Kg).

10-3280

5 mg / \$55.00, 25 mg / \$180.00

